Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype
Cells · 2024
DOI: 10.3390/cells13181534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Ahmed F Pantho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Artemis Biotechnologies LLC, Temple, TX 76504, USA. Hauptthemen laut MEDLINE: Pravastatin, Pre-Eclampsia, Trophoblasts, Hyperglycemia. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scott, Sherwood and Brindley Foundation, Department of Obstetrics and Gynecology (MNU), Noble Centennial Endowment for Research in Obstetrics and Gynecology.
Abstract (Originalsprache)
There are no effective therapies to prevent preeclampsia (PE). Pravastatin shows promise by attenuating processes associated with PE such as decreased cytotrophoblast (CTB) migration, aberrant angiogenesis, and increased oxidative stress. This study assesses the effects of pravastatin on hyperglycemia-induced CTB dysfunction.
Methods
Human CTB cells were treated with 100, 150, 200, 300, or 400 mg/dL glucose for 48 h. Some cells were pretreated with pravastatin (1 µg/mL), while others were cotreated with pravastatin and glucose. The expression of urokinase plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1) mRNA, vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and soluble endoglin (sEng) were measured. CTB migration was assayed using a CytoSelect migration assay kit. Statistical comparisons were performed using an analysis of variance with Duncan’s post hoc test.
Results
The hyperglycemia-induced downregulation of uPA was attenuated in CTB cells pretreated with pravastatin at glucose levels > 200 mg/dL and cotreated at glucose levels > 300 mg/dL (p < 0.05). Hyperglycemia-induced decreases in VEGF and PlGF and increases in sEng and sFlt-1 were attenuated in both the pretreatment and cotreatment samples regardless of glucose dose (p < 0.05). Pravastatin attenuated hyperglycemia-induced dysfunction of CTB migration.
Conclusions
Pravastatin mitigates stress signaling responses in hyperglycemic conditions, weakening processes leading to abnormal CTB migration and invasion associated with PE in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Artemis Biotechnologies LLC, Temple, TX 76504, USA.
- Baylor Scott & White Health, Temple, TX 76508, USA.
- University of Texas Medical School at Houston, Houston, TX 77030, USA.
- Texas A&M University College of Medicine, College Station, TX 77807, USA.
ORCID-Profile: Niraj Vora, Mohammad N Uddin
Förderung
- Scott, Sherwood and Brindley Foundation
- Department of Obstetrics and Gynecology (MNU)
- Noble Centennial Endowment for Research in Obstetrics and Gynecology
- Baylor Scott & White Healthcare, Temple, Texas
Zitieren
APA
Pantho, A. F., Mohamed, S., Govande, J. V., Rane, R., Vora, N., Kelso, K. R., Kuehl, T. J., Lindheim, S. R., & Uddin, M. N. (2024). Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. https://doi.org/10.3390/cells13181534
Vancouver
Pantho AF, Mohamed S, Govande JV, Rane R, Vora N, Kelso KR, et al. Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024. doi:10.3390/cells13181534
BibTeX
@article{Pantho2024,
author = {Pantho, Ahmed F and Mohamed, Sara and Govande, Janhavi V and Rane, Riddhi and Vora, Niraj and Kelso, Kelsey R and Kuehl, Thomas J and Lindheim, Steven R and Uddin, Mohammad N},
title = {Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181534}
}
EUVIMED